RadNet, Inc. (NASDAQ:RDNT – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $89.67.
RDNT has been the topic of several research reports. Raymond James Financial restated a “strong-buy” rating on shares of RadNet in a report on Tuesday, September 22nd. Barclays boosted their price objective on shares of RadNet from $65.00 to $79.00 and gave the stock an “overweight” rating in a research note on Friday, August 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of RadNet in a research report on Wednesday, November 4th. Jefferies Financial Group reissued a “buy” rating on shares of RadNet in a research note on Friday, July 31st. Finally, Zacks Research lowered shares of RadNet from a “strong-buy” rating to a “hold” rating in a report on Monday, November 9th.
Read Our Latest Stock Report on RadNet
Insider Transactions at RadNet
Institutional Investors Weigh In On RadNet
Several hedge funds have recently modified their holdings of RDNT. Bank of America Corp DE boosted its holdings in RadNet by 15.1% in the 1st quarter. Bank of America Corp DE now owns 589,610 shares of the medical research company’s stock worth $32,953,000 after acquiring an additional 77,198 shares during the period. Edmond DE Rothschild Holding S.A. acquired a new stake in RadNet in the second quarter valued at approximately $1,172,000. Legal & General Group Plc acquired a new stake in RadNet in the second quarter valued at approximately $9,787,000. California State Teachers Retirement System raised its stake in shares of RadNet by 25.4% during the first quarter. California State Teachers Retirement System now owns 77,646 shares of the medical research company’s stock valued at $4,340,000 after purchasing an additional 15,746 shares during the period. Finally, Hsbc Holdings PLC purchased a new stake in shares of RadNet during the second quarter valued at approximately $1,163,000. 77.90% of the stock is currently owned by hedge funds and other institutional investors.
RadNet Stock Performance
RadNet stock opened at $69.71 on Friday. The stock’s 50-day moving average is $72.71 and its 200-day moving average is $65.56. The company has a market cap of $5.49 billion, a price-to-earnings ratio of -240.38 and a beta of 1.42. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.49 and a quick ratio of 1.49. RadNet has a 12 month low of $50.82 and a 12 month high of $85.84.
RadNet (NASDAQ:RDNT – Get Free Report) last issued its earnings results on Sunday, November 8th. The medical research company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.08. RadNet had a positive return on equity of 3.14% and a negative net margin of 0.94%. The business had revenue of $638.26 million during the quarter, compared to analysts’ expectations of $639.97 million. During the same quarter in the previous year, the business earned $0.20 EPS. The company’s revenue for the quarter was up 22.1% on a year-over-year basis. Equities analysts anticipate that RadNet will post 0.56 earnings per share for the current year.
RadNet Company Profile
RadNet, Inc. operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging. The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.
Featured Stories
- Five stocks we like better than RadNet
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.
